Search results for " therapies"

showing 10 items of 112 documents

Leishmaniasis and Biologic Therapies for Rheumatologic Diseases

2010

In his article in Seminars in Arthritis and Rheumatism,Furst (1) provides an accurate analysis of the infec-tions that are related to the use of biologic therapiesfor rheumatoid arthritis. We would like to addLeishma-niaspp to the list of the infectious agents that can causedisease during the course of biologic therapies.

medicine.medical_specialtyLeishmaniasis Rheumatologic DiseasesAnesthesiology and Pain MedicineRheumatologybusiness.industryBiologic therapiesmedicineLeishmaniasismedicine.diseasebusinessDermatologySeminars in Arthritis and Rheumatism
researchProduct

Tai Chi for Chronic Illness Management: Synthesizing Current Evidence from Meta-Analyses of Randomized Controlled Trials

2021

An umbrella review of systematic reviews and meta-analyses of randomized controlled trials (RCTs) was conducted to evaluate the existing evidence of Tai Chi as a mind-body exercise for chronic illness management. MEDLINE/PubMed and Embase databases were searched from inception until March 31, 2019, for meta-analyses of at least two RCTs that investigated health outcomes associated with Tai Chi intervention. Evidence of significant outcomes (P value < 0.05) was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. This review identified 45 meta-analyses of RCTs and calculated 142 summary estimates among adults living with 16 types of chronic …

medicine.medical_specialtyMind-body exerciseMEDLINE030204 cardiovascular system & hematologyHealth outcomesTai Chilaw.inventionUmbrella review03 medical and health sciences0302 clinical medicineRandomized controlled trialMeta-Analysis as TopiclawChronic illness managementmedicineChronic illneHumans030212 general & internal medicineRandomized Controlled Trials as Topicbusiness.industryMind-Body TherapiesGeneral MedicinePeer reviewMind/body exerciseSystematic reviewRandomized controlled trialChronic DiseasePhysical therapyQuality of LifeTai Jibusiness
researchProduct

Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers

2015

Introduction Natalizumab (NTZ) discontinuation can be followed by multiple sclerosis (MS) disease reactivation. Currently no disease-modifying drug (DMD) has been shown to be able to abolish disease reactivation. The aims of the current study were: (1) to determine the frequency of MS reactivation after NTZ discontinuation; (2) to evaluate predictors of reactivation risk, and (3) to compare the effect of different treatments in reducing this risk. Methods Data from 132 patients with MS followed-up for 2 years before NTZ treatment and 1 year after interruption were collected from two Italian MS centers and retrospectively evaluated. Results Overall, 72 of 132 patients (54.5%) had relapses af…

medicine.medical_specialtyNeurologyNatalizumab discontinuationDiseasePharmacologyMultiple sclerosisNatalizumabInternal medicineparasitic diseasesDisease reactivationmedicineMultiple sclerosiIn patientFirst-line therapieOriginal ResearchDisease reactivation; First-line therapies; Multiple sclerosis; Natalizumab discontinuation; Rebound; Second-line therapies; Neurology (clinical); NeurologyFirst-line therapiesReboundSecond-line therapiebusiness.industryMultiple sclerosisRetrospective cohort studymedicine.diseaseDiscontinuationNeurologyTreatment strategyNeurology (clinical)businessSecond-line therapiesmedicine.drug
researchProduct

Combination of Rehabilitative Therapy with Ultramicronized Palmitoylethanolamide for Chronic Low Back Pain: An Observational Study

2019

Abstract Introduction Chronic low back pain (LBP) caused by intervertebral disc herniation was reported in the 2010 Global Burden of Disease study to be the main reason for years lived with disability. It causes significant personal, social, and economic burdens. Many of those who suffer from LBP find conventional medical treatments to be unsatisfactory for treating their pain, so they are increasingly resorting to complementary and alternative medicine (CAM) therapies. Given that the population is aging, there is an urgent need to characterize the combinations of complementary therapies that yield the best outcomes and treatments, even for prolonged periods. This observational study aimed …

medicine.medical_specialtyPain medicinePopulationlcsh:RD78.3-87.3Quality of lifeMedicineMultitarget approachNdultidisciplinary therapir:educationComplementary and alternative medicirreeducation.field_of_studyMassagebusiness.industryBrief ReportUltramicronized palmitlethanolamideChronic low back pajnChronic painmedicine.diseaseUltramicronized palmitoylethanolamideLow back painAnesthesiology and Pain MedicineComplementary and alternative medicinelcsh:AnesthesiologyMultidisciplinary therapiesPhysical therapyChronic low back painMcKenzie methodObservational studyNeurology (clinical)medicine.symptombusinessPain and Therapy
researchProduct

Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement

2020

Genome sequencing and gene-based therapies appear poised to advance the management of rare lipoprotein disorders and associated dyslipidaemias. However, in practice, underdiagnosis and undertreatment of these disorders are common, in large part due to interindividual variability in the genetic causes and phenotypic presentation of these conditions. To address these challenges, the European Atherosclerosis Society formed a task force to provide practical clinical guidance focusing on patients with extreme concentrations (either low or high) of plasma low-density lipoprotein cholesterol, triglycerides, or high-density lipoprotein cholesterol. The task force also recognises the scarcity of qua…

medicine.medical_specialtyRare dyslipidaemiaConsensusSettore MED/09 - Medicina InternaGenotypediagnosisEndocrinology Diabetes and MetabolismMEDLINE030209 endocrinology & metabolism610 Medicine & health03 medical and health sciences0302 clinical medicineEndocrinologyRare DiseasesGenotype540 ChemistryInternal Medicinemedicinegeneome sequencingHumansgeneticsGenetic Predisposition to DiseaseRare dyslipidemias; genetics; diagnosis; treatment030212 general & internal medicineDisease management (health)Intensive care medicineHealth policyDyslipidemias10038 Institute of Clinical Chemistrytreatmentbusiness.industryTask forcegene therapiesDisease ManagementAtherosclerosisPhenotype1310 EndocrinologyEurope2712 Endocrinology Diabetes and MetabolismPhenotype2724 Internal MedicinePractice Guidelines as TopicRare dyslipidemiasEuropean atherosclerosis societylipids (amino acids peptides and proteins)businessQuality information
researchProduct

Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

2020

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is creating an unprecedented global public health emergency with the continuous growth of infected individuals worldwide. Italy was one of the first European country to face the first wave of infection outside mainland China. The first case of COVID-19 was confirmed in Lombardy on February 20th , 2020, and subsequently, a rapid increase in the number of detected cases was observed, spreading through Italy and the rest of Europe.3 As of April 22nd , confirmed COVID-19 cases in Italy were 183,957.

medicine.medical_specialtyTildrakizumabBiolgical therapy; COVID-19; PsoriasisSettore MED/35PsoriasisChronic Disease; Emergencies; Humans; Italy; Psoriasis; Biological Therapy; COVID-19UstekinumabmedicineAdalimumabHumansPsoriasisbiologicsIntensive care medicineLetter to the Editorpsoriasipsoriasis; biologics; covid-19; pandemicEmergenciePsoriasiRisankizumabbusiness.industrySARS-CoV-2pandemicBiolgical therapyCOVID-19medicine.diseasedermatologyBiological TherapyIxekizumabGuselkumabInfectious Diseasescovid-19ItalyChronic DiseaseSecukinumabEmergenciesbusinessSettore MED/35 - MALATTIE CUTANEE E VENEREEbiologicCOVID-19 psoriasis biological therapiesmedicine.drugHuman
researchProduct

Investigational agents for Crohn's disease.

2010

IMPORTANCE OF THE FIELD: Increased understanding of the biological mechanisms of Crohn's disease has opened the door to a large number of new molecules; some of these are approved for clinical use, while others remain under evaluation. In this review, we examine the clinical efficacy of all the new drugs that have been evaluated in controlled trials in the last 12 years. AREAS COVERED IN THIS REVIEW: Anti-TNF therapy has been reviewed briefly, given the many comprehensive reviews on this topic; attention is focused mainly on the other biological therapies. In assessing the clinical efficacy of these molecules, we consider only the remission rate, as this is considered the most meaningful en…

medicine.medical_specialtybiological therapy. Crohn' s disease. Integrins.Probiotics.Small molecules.DiseaseAdaptive ImmunityReceptors Tumor Necrosis FactorCrohn DiseaseGastrointestinal AgentsmedicineHumansImmunologic FactorsPharmacology (medical)Clinical efficacyIntensive care medicineRandomized Controlled Trials as TopicPharmacologyMitogen-Activated Protein Kinase KinasesBiological therapiesCrohn's diseaseEverolimusEnd pointINVESTIGATIONAL AGENTSbusiness.industryRemission InductionAntibodies MonoclonalGeneral MedicineDrugs Investigationalmedicine.diseaseImmunity InnateImmunologyCytokinesRemission rateImmunotherapybusinessCell Adhesion Moleculesmedicine.drugExpert opinion on investigational drugs
researchProduct

The efficacy of muscle energy techniques in symptomatic and asymptomatic subjects: a systematic review

2019

Abstract Background Muscle energy techniques are applied to reduce pain and increase range of motion. These are applied to a variety of pathological conditions and on asymptomatic subjects. There is however limited knowledge on their effectiveness and which protocol may be the most beneficial. Objective The aim of this review is to determine the efficacy of muscle energy techniques (MET) in symptomatic and asymptomatic subjects. Design Systematic Review. Methods A literature search was performed using the following database: Cochrane Library, MEDLINE, NLM Pubmed and ScienceDirect. Studies regarding MET in asymptomatic and symptomatic patients were considered for investigation. The main outc…

medicine.medical_specialtylcsh:Diseases of the musculoskeletal systemmedicine.medical_treatmentMEDLINEPainPhysical Therapy Sports Therapy and RehabilitationCochrane LibraryAsymptomaticlaw.invention03 medical and health sciencesManipulative therapie0302 clinical medicineRandomized controlled triallawMedicineHumans030212 general & internal medicineRange of Motion ArticularPathologicalRange of motionRandomized Controlled Trials as TopicRehabilitationbusiness.industryEpicondylitisMuscleslcsh:Chiropracticmedicine.diseaseManipulation OsteopathicAcute PainTreatment OutcomeComplementary and alternative medicinelcsh:RZ201-275Asymptomatic DiseasesPhysical therapyChiropracticsSystematic Reviewlcsh:RC925-935medicine.symptomChronic PainRange of motionbusinessManipulative therapies030217 neurology & neurosurgeryChiropractic & Manual Therapies
researchProduct

Novel cytokine-targeted therapies and intestinal inflammation

2009

Several cytokines have been identified as critical mediators of chronic inflammation in inflammatory bowel disease (IBD) and biological therapies that target these molecules have been developed during recent years. Thereby, anti-TNF agents have noticeably improved the treatment of patients with IBD in comparison to conventional therapy. Furthermore, initial clinical trials showed promising results with anti-IL-6 and anti-IL-12/IL-23 agents. In addition to these well-known mediators of IBD, various novel cytokines have been described as critical during the pathogenesis of IBD in recent experimental studies and therapeutic targeting of these cytokines could provide new strategies for human di…

medicine.medical_treatmentInflammationTherapeutic targetingInflammatory bowel diseaseAntibodiesPathogenesisDrug Delivery SystemsIntestinal inflammationDrug DiscoverymedicineAnimalsHumansIntestinal MucosaPharmacologyBiological therapiesbusiness.industryModels ImmunologicalColitisInflammatory Bowel Diseasesmedicine.diseasedigestive system diseasesIntestinesClinical trialDisease Models AnimalCytokineImmunologyCytokinesmedicine.symptombusinessCurrent Opinion in Pharmacology
researchProduct

Antioxidant Therapies and Oxidative Stress in Friedreich´s Ataxia: The Right Path or Just a Diversion?

2020

Friedreich's ataxia is the commonest autosomal recessive ataxia among population of European descent. Despite the huge advances performed in the last decades, a cure still remains elusive. One of the most studied hallmarks of the disease is the increased production of oxidative stress markers in patients and models. This feature has been the motivation to develop treatments that aim to counteract such boost of free radicals and to enhance the production of antioxidant defenses. In this work, we present and critically review those 'antioxidant' drugs that went beyond the disease's models and were approved for its application in clinical trials. The evaluation of these trials highlights some …

reactive oxygen speciesFriedreich’s ataxia; clinical trials; oxidative stress; antioxidant therapies; reactive oxygenspecies; scavengers; antioxidant response; mitochondrial metabolism; ferroptosisclinical trialsmitochondrial metabolismantioxidant responseEstrès oxidatiulcsh:RM1-950Friedreich’s ataxiaReviewFriedreich´s ataxia590 Tiere (Zoologie)Antioxidantsferroptosisscavengerslcsh:Therapeutics. Pharmacology570 Biowissenschaften Biologieddc:590oxidative stressantioxidant therapiesddc:570Antioxidants
researchProduct